These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
358 related articles for article (PubMed ID: 23950184)
1. High doses of infliximab in the management of juvenile idiopathic arthritis. Tambralli A; Beukelman T; Weiser P; Atkinson TP; Cron RQ; Stoll ML J Rheumatol; 2013 Oct; 40(10):1749-55. PubMed ID: 23950184 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study. Gerloni V; Pontikaki I; Gattinara M; Desiati F; Lupi E; Lurati A; Salmaso A; Fantini F Arthritis Rheum; 2005 Feb; 52(2):548-53. PubMed ID: 15693004 [TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry. Zannin ME; Birolo C; Gerloni VM; Miserocchi E; Pontikaki I; Paroli MP; Bracaglia C; Shardlow A; Parentin F; Cimaz R; Simonini G; Falcini F; Corona F; Viola S; De Marco R; Breda L; La Torre F; Vittadello F; Martini G; Zulian F J Rheumatol; 2013 Jan; 40(1):74-9. PubMed ID: 23118110 [TBL] [Abstract][Full Text] [Related]
4. Infliximab in pediatric rheumatology patients: a retrospective analysis of infusion reactions and severe adverse events during 2246 infusions over 12 years. Aeschlimann FA; Hofer KD; Cannizzaro Schneider E; Schroeder S; Lauener R; Saurenmann RK J Rheumatol; 2014 Jul; 41(7):1409-15. PubMed ID: 24833759 [TBL] [Abstract][Full Text] [Related]
5. [Long-term evaluation of infliximab in the treatment of persistently active juvenile idiopathic arthritis refractory to conventional therapy]. De Marco G; Gerloni V; Pontikaki I; Luriati A; Teruzzi B; Salmaso A; Valcamonica E; Gattinara M; Fantini F Reumatismo; 2007; 59(1):50-6. PubMed ID: 17435842 [TBL] [Abstract][Full Text] [Related]
6. Longterm Safety and Efficacy of Adalimumab and Infliximab for Uveitis Associated with Juvenile Idiopathic Arthritis. Cecchin V; Zannin ME; Ferrari D; Pontikaki I; Miserocchi E; Paroli MP; Bracaglia C; Marafon DP; Pastore S; Parentin F; Simonini G; De Libero C; Falcini F; Petaccia A; Filocamo G; De Marco R; La Torre F; Guerriero S; Martino S; Comacchio F; Muratore V; Martini G; Vittadello F; Zulian F J Rheumatol; 2018 Aug; 45(8):1167-1172. PubMed ID: 29657140 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry. Schmeling H; Minden K; Foeldvari I; Ganser G; Hospach T; Horneff G Arthritis Rheumatol; 2014 Sep; 66(9):2580-9. PubMed ID: 24942886 [TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ruperto N; Lovell DJ; Cuttica R; Woo P; Meiorin S; Wouters C; Silverman ED; Balogh Z; Henrickson M; Davidson J; Foeldvari I; Imundo L; Simonini G; Oppermann J; Xu S; Shen YK; Visvanathan S; Fasanmade A; Mendelsohn A; Martini A; Giannini EH; ; Ann Rheum Dis; 2010 Apr; 69(4):718-22. PubMed ID: 20237125 [TBL] [Abstract][Full Text] [Related]
9. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial. Tynjälä P; Vähäsalo P; Tarkiainen M; Kröger L; Aalto K; Malin M; Putto-Laurila A; Honkanen V; Lahdenne P Ann Rheum Dis; 2011 Sep; 70(9):1605-12. PubMed ID: 21623000 [TBL] [Abstract][Full Text] [Related]
10. Prevalence of Anti-infliximab Antibodies and Their Associated Co-factors in Children with Refractory Arthritis and/or Uveitis: A Retrospective Longitudinal Cohort Study. Aeschlimann FA; Angst F; Hofer KD; Cannizzaro Schneider E; Schroeder-Kohler S; Lauener R; van der Kleij D; Rispens T; Saurenmann RK J Rheumatol; 2017 Mar; 44(3):334-341. PubMed ID: 28089968 [TBL] [Abstract][Full Text] [Related]
11. Children with juvenile idiopathic arthritis frequently experience interruptions to their medical therapy. Kazamia K; Holmquist L; Fagerlund A; Berntson L Acta Paediatr; 2014 May; 103(5):529-36. PubMed ID: 24517256 [TBL] [Abstract][Full Text] [Related]
12. Therapeutic effects of the anti-tumor necrosis factor monoclonal antibody, infliximab, in four children with refractory juvenile idiopathic arthritis. Norambuena R X; Mallol J; Ríos M G; Quevedo R F; Quezada L A Allergol Immunopathol (Madr); 2007; 35(2):52-6. PubMed ID: 17428400 [TBL] [Abstract][Full Text] [Related]
13. Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA). Klotsche J; Niewerth M; Haas JP; Huppertz HI; Zink A; Horneff G; Minden K Ann Rheum Dis; 2016 May; 75(5):855-61. PubMed ID: 25926155 [TBL] [Abstract][Full Text] [Related]
14. Prediction of methotrexate intolerance in juvenile idiopathic arthritis: a prospective, observational cohort study. van Dijkhuizen EH; Bulatović Ćalasan M; Pluijm SM; de Rotte MC; Vastert SJ; Kamphuis S; de Jonge R; Wulffraat NM Pediatr Rheumatol Online J; 2015; 13():5. PubMed ID: 25745368 [TBL] [Abstract][Full Text] [Related]
15. Health-related quality of life during early aggressive treatment in patients with polyarticular juvenile idiopathic arthritis: results from randomized controlled trial. Tarkiainen M; Tynjälä P; Vähäsalo P; Kröger L; Aalto K; Lahdenne P Pediatr Rheumatol Online J; 2019 Dec; 17(1):80. PubMed ID: 31842940 [TBL] [Abstract][Full Text] [Related]
16. Leflunomide is associated with a higher flare rate compared to methotrexate in the treatment of chronic uveitis in juvenile idiopathic arthritis. Bichler J; Benseler SM; Krumrey-Langkammerer M; Haas JP; Hügle B Scand J Rheumatol; 2015; 44(4):280-3. PubMed ID: 25993023 [TBL] [Abstract][Full Text] [Related]
17. Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial. Brunner HI; Ruperto N; Tzaribachev N; Horneff G; Chasnyk VG; Panaviene V; Abud-Mendoza C; Reiff A; Alexeeva E; Rubio-Pérez N; Keltsev V; Kingsbury DJ; Del Rocio Maldonado Velázquez M; Nikishina I; Silverman ED; Joos R; Smolewska E; Bandeira M; Minden K; van Royen-Kerkhof A; Emminger W; Foeldvari I; Lauwerys BR; Sztajnbok F; Gilmer KE; Xu Z; Leu JH; Kim L; Lamberth SL; Loza MJ; Lovell DJ; Martini A; Ann Rheum Dis; 2018 Jan; 77(1):21-29. PubMed ID: 28507219 [TBL] [Abstract][Full Text] [Related]
18. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis. Tynjälä P; Vähäsalo P; Honkanen V; Lahdenne P Ann Rheum Dis; 2009 Apr; 68(4):552-7. PubMed ID: 18467515 [TBL] [Abstract][Full Text] [Related]
19. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Tynjälä P; Lindahl P; Honkanen V; Lahdenne P; Kotaniemi K Ann Rheum Dis; 2007 Apr; 66(4):548-50. PubMed ID: 17068061 [TBL] [Abstract][Full Text] [Related]